Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma

The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml. In our prospectively registered, real-world cohort, 13 and 11 pa...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2021-04, Vol.41 (4), p.2187-2192
Main Authors: Maesaka, Kazuki, Sakamori, Ryotaro, Yamada, Ryoko, Tahata, Yuki, Ohkawa, Kazuyoshi, Oshita, Masahide, Tamura, Shinji, Hagiwara, Hideki, Mita, Eiji, Yakushijin, Takayuki, Inada, Masami, Kodama, Takahiro, Hikita, Hayato, Tatsumi, Tomohide, Takehara, Tetsuo
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
alpha-Fetoproteins - metabolism
Antibodies, Monoclonal, Humanized - therapeutic use
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Chemotherapy, Adjuvant - methods
Cohort Studies
Disease control
Disease Progression
Female
Hepatocellular carcinoma
Humans
Japan - epidemiology
Liver cancer
Liver Neoplasms - blood
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Male
Middle Aged
Progression-Free Survival
Ramucirumab
Sorafenib - therapeutic use
Stability
Survival Rate
Treatment Outcome
α-Fetoprotein
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml. In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, were analyzed. Progression-free survival (PFS) was primarily compared between the ramucirumab and sorafenib groups. The PFS was significantly longer in the ramucirumab group than in the sorafenib group (median, 2.7 vs. 0.9 months, respectively; p=0.005). There were no significant differences in the objective response rates or the disease control rates between the ramucirumab and sorafenib groups (9.1% and 54.5% vs. 0.0% and 22.2%, respectively). Subsequent systemic therapy with ramucirumab showed a better ability to control tumor progression than sorafenib in HCC patients with serum AFP levels ≥400 ng/ml.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14993